Rosty Raykov Sells 10,000 Shares of Fennec Pharmaceuticals Inc (NASDAQ:FENC) Stock

Fennec Pharmaceuticals Inc (NASDAQ:FENC - Get Free Report) Director Rosty Raykov sold 10,000 shares of the firm's stock in a transaction dated Friday, April 4th. The stock was sold at an average price of $5.25, for a total transaction of $52,500.00. Following the sale, the director now directly owns 61,156 shares in the company, valued at $321,069. This represents a 14.05 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Rosty Raykov also recently made the following trade(s):

• On Wednesday, March 5th, Rosty Raykov sold 10,000 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of $6.79, for a total value of $67,900.00.
• On Wednesday, February 5th, Rosty Raykov sold 10,000 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of $6.66, for a total value of $66,600.00.
• On Monday, January 6th, Rosty Raykov sold 10,000 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of $6.08, for a total value of $60,800.00.

Fennec Pharmaceuticals Trading Down 5.2 %

Shares of Fennec Pharmaceuticals stock traded down $0.26 during trading hours on Wednesday, reaching $4.75. The stock had a trading volume of 17,802 shares, compared to its average volume of 79,913. The firm has a market capitalization of $131.04 million, a price-to-earnings ratio of -47.50 and a beta of 0.32. Fennec Pharmaceuticals Inc has a 1 year low of $3.96 and a 1 year high of $11.11. The firm has a 50 day simple moving average of $6.43 and a two-hundred day simple moving average of $5.72.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the business. Intech Investment Management LLC acquired a new stake in shares of Fennec Pharmaceuticals in the fourth quarter worth $69,000. Wells Fargo & Company MN boosted its position in Fennec Pharmaceuticals by 31.6% during the 4th quarter. Wells Fargo & Company MN now owns 13,152 shares of the company's stock worth $83,000 after purchasing an additional 3,155 shares during the period. Franklin Resources Inc. increased its holdings in Fennec Pharmaceuticals by 18.7% in the 3rd quarter. Franklin Resources Inc. now owns 14,799 shares of the company's stock valued at $74,000 after purchasing an additional 2,330 shares in the last quarter. Pinnacle Wealth Planning Services Inc. purchased a new position in Fennec Pharmaceuticals in the fourth quarter valued at about $97,000. Finally, MetLife Investment Management LLC purchased a new position in Fennec Pharmaceuticals in the fourth quarter valued at about $99,000. Hedge funds and other institutional investors own 55.51% of the company's stock.

Analyst Ratings Changes

A number of research firms have recently commented on FENC. HC Wainwright reaffirmed a "buy" rating and set a $13.00 price objective on shares of Fennec Pharmaceuticals in a research note on Tuesday, March 11th. Wedbush reaffirmed an "outperform" rating and set a $13.00 price target on shares of Fennec Pharmaceuticals in a research note on Monday, March 10th.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.